Atsushi Hagihara

Clinical relevance of serum full-length glypican-3 in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

Abstract Biomarkers that can predict patient survival and the therapeutic response to atezolizumab and bevacizumab (Atezo/Bev) as first-line chemotherapy for unresectable hepatocellular carcinoma (HCC) have yet to be identified. We aimed to determine whether the serum full-length...